DermTech (NASDAQ: DMTK) is one of 37 public companies in the “Medical laboratories” industry, but how does it weigh in compared to its rivals? We will compare DermTech to similar companies based on the strength of its dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
Earnings & Valuation
This table compares DermTech and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|DermTech||$3.36 million||-$19.69 million||-3.98|
|DermTech Competitors||$847.25 million||$39.63 million||78.01|
This is a summary of recent recommendations and price targets for DermTech and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
DermTech presently has a consensus target price of $22.00, indicating a potential upside of 96.60%. As a group, “Medical laboratories” companies have a potential upside of 10.13%. Given DermTech’s stronger consensus rating and higher probable upside, analysts clearly believe DermTech is more favorable than its rivals.
Institutional and Insider Ownership
50.1% of DermTech shares are held by institutional investors. Comparatively, 46.5% of shares of all “Medical laboratories” companies are held by institutional investors. 16.5% of DermTech shares are held by insiders. Comparatively, 16.1% of shares of all “Medical laboratories” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares DermTech and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
DermTech has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, DermTech’s rivals have a beta of 1.19, indicating that their average share price is 19% more volatile than the S&P 500.
DermTech rivals beat DermTech on 8 of the 13 factors compared.
DermTech Company Profile
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.